Distribution of Hepatitis C Risk Factors and HCV Treatment Outcomes among Central Canadian Aboriginal

Canadian Journal of Gastroenterology and Hepatology

Volumn 2016, Issue , 2016, Pages

  Parmar, Parmvir ^a,b   Corsi, Daniel J ^b   Cooper, Curtis ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INTERFERON;

ADULT; ARTICLE; CANADIAN; FEMALE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIGENOUS PEOPLE; INFECTION RISK; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIXED INFECTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK FACTOR; SUBSTANCE ABUSE; TREATMENT OUTCOME; AGE DISTRIBUTION; AMERICAN INDIAN; COHORT ANALYSIS; ETHNOLOGY; HEPACIVIRUS; MIDDLE AGED; ODDS RATIO; ONTARIO; SEX RATIO; SOCIAL CLASS; STATISTICS AND NUMERICAL DATA;

ADULT; AGE DISTRIBUTION; ANTIVIRAL AGENTS; COHORT STUDIES; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; INDIANS, NORTH AMERICAN; MALE; MIDDLE AGED; ODDS RATIO; ONTARIO; RISK FACTORS; SEX DISTRIBUTION; SOCIAL CLASS; TREATMENT OUTCOME;

EID: 84971393517     PISSN: 22912789     EISSN: 22912797     Source Type: Journal    
DOI: 10.1155/2016/8987976     Document Type: Article

References (28)

1. R. Baden, J. K. Rockstroh, and M. Buti, "Natural history and management of hepatitis C: does sex play a role?" Journal of Infectious Diseases, vol. 209, supplement 3, pp. S81-S85, 2014.
2. B. Hajarizadeh, J. Grebely, and G. J. Dore, "Epidemiology and natural history of HCV infection, " Nature Reviews Gastroenterology and Hepatology, vol. 10, no. 9, pp. 553-562, 2013.
3. J. McCombs, T. Matsuda, I. Tonnu-Mihara et al., "The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a department of veterans affairs clinical registry, " JAMAInternalMedicine, vol. 174, no. 2, pp. 204-212, 2014.
4. R. P. Myers, M. Krajden, M. Bilodeau et al., "Burden of disease and cost of chronic hepatitis C infection in Canada, " Canadian Journal of Gastroenterology&Hepatology, vol. 28, no. 5, pp. 243-250, 2014.
5. R. J. Harris, B. Thomas, J. Griffiths et al., "Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: modelling the predicted impact of treatment under different scenarios, " Journal of Hepatology, vol. 61, no. 3, pp. 530-537, 2014.
6. F. S. Mennini, A. Marcellusi, M. Andreoni, A. Gasbarrini, S. Salomone, and A. Crax, "Health policy model: long-term predictive results associatedwith themanagement of hepatitisC virus-induced diseases in Italy, " ClinicoEconomics andOutcomes Research, vol. 6, no. 1, pp. 303-310, 2014.
7. Z. M. Younossi, M. Otgonsuren, L. Henry et al., "Inpatient resource utilization, disease severity, mortality and insurance coverage for patients hospitalized for hepatitis C virus in the United States, " Journal of Viral Hepatitis, vol. 22, no. 2, pp. 137-145, 2015.
8. C. L. Cooper, R. J. Bailey, V. G. Bain et al., "Outcomes of peginterferon alpha-2a and ribavirin hepatitis C therapy in Aboriginal Canadians, " Canadian Journal of Gastroenterology, vol. 22, no. 8, pp. 677-680, 2008.
9. K. J. P. Craib, P. M. Spittal, S. H. Patel et al., "Prevalence and incidence of hepatitis C virus infection among aboriginal young people who use drugs: results from the Cedar Project, " Open Medicine, vol. 3, no. 4, pp. e220-e227, 2009.
10. P. M. Spittal, M. E. Pearce, N. Chavoshi et al., "The Cedar Project: high incidence of HCV infections in a longitudinal study of young Aboriginal people who use drugs in two Canadian cities, " BMC Public Health, vol. 12, article 632, 2012.
11. S. Y. Shaw, K. N. Deering, A. M. Jolly, and J. L. Wylie, "Increased risk for hepatitis C associated with solvent use among Canadian Aboriginal injection drug users, " Harm Reduction Journal, vol. 7, article 16, 2010.
12. H. X. Wu, J. Wu, T. Wong et al., "Incidence and risk factors for newly acquired hepatitis C virus infection among Aboriginal versus non-Aboriginal Canadians in six regions, 1999-2004, " The European Journal of Clinical Microbiology & Infectious Diseases, vol. 26, no. 3, pp. 167-174, 1999.
13. M. Alavi, J. D. Raffa, G. D. Deans et al., "Continued lowuptakeof treatment for hepatitis C virus infection in a large communitybased cohort of inner city residents, " Liver International, vol. 34, no. 8, pp. 1198-1206, 2014.
14. M. Dawood, G. Smart, M. Wood, H.-X. Wu, S. Paton, and J. Wu, "Hepatitis C virus infection among First Nation and non-First Nation people in Manitoba, Canada-a public health laboratory study, " Canadian Journal of Microbiology, vol. 52, no. 10, pp. 999-1005, 2006.
15. G. Y. Minuk and J. Uhanova, "Viral hepatitis in the Canadian Iuit and First Nations populations, " Canadian Journal of Gastroenterology, vol. 17, no. 12, pp. 707-712, 2003.
16. J. D. Rempel and J. Uhanova, "Hepatitis C virus in American Indian/Alaskan native and Aboriginal peoples of North America, " Viruses, vol. 4, no. 12, pp. 3912-3931, 2012.
17. J. D. Scott and N. Garland, "Chronic liver disease in aboriginal northAmericans, "World Journal ofGastroenterology, vol. 14, no. 29, pp. 4607-4615, 2008.
18. A. Suryaprasad, K. K. Byrd, J. T. Redd, D. G. Perdue, M. M. Manos, and B. J. McMahon, "Mortality caused by chronic liver disease among American Indians and Alaska Natives in the United States, 1999-2009, " American Journal of Public Health, vol. 104, supplement 3, pp. S350-S358, 2014.
19. M. Alavi, J. Grebely, M. Micallef et al., "Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study, " Clinical Infectious Diseases, vol. 57, supplement 2, pp. S62-S69, 2013.
20. G. Y. Minuk, M. O'Brien, K. Hawkins et al., "Treatment of chronic hepatitisCin aCanadianAboriginal population: results from the PRAIRIE study, " Canadian Journal of Gastroenterology, vol. 27, no. 12, pp. 707-710, 2013.
21. M. B. Klein, K. C. Rollet, S. Saeed et al., "HIV and hepatitis C virus coinfection in Canada: challenges and opportunities for reducing preventable morbidity and mortality, " HIV Medicine, vol. 14, no. 1, pp. 10-20, 2013.
22. R. Pampalon, D. Hamel, P. Gamache, and G. Raymond, "A deprivation index for health planning in Canada, " Chronic Diseases in Canada, vol. 29, no. 4, pp. 178-191, 2009.
23. T. Berg, C. Sarrazin, E. Herrmann et al., "Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy, " Hepatology, vol. 37, no. 3, pp. 600-609, 2003.
24. M. Imran, S. Manzoor, J. Ashraf et al., "Role of viral and host factors in interferon based therapy of hepatitis C virus infection, " Virology Journal, vol. 10, article 299, 2013.
25. S. B. Rourke, M. Sobota, R. Tucker et al., "Social determinants of health associated with hepatitis C co-infection among people living with HIV: results fromthe Positive Spaces, Healthy Places study, " Open Medicine, vol. 5, no. 3, pp. e120-e131, 2011.
26. Public Health Agency of Canada, "HIV/AIDS Epi updates: national HIV prevalence and incidence estimates for 2011, " in Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, 2014.
27. S. B. Missiha, M. Ostrowski, and E. J. Heathcote, "Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors, " Gastroenterology, vol. 134, no. 6, pp. 1699-1714, 2008.
28. J. D. Rempel, K. Hawkins, E. Lande, and P. Nickerson, "The potential influence of KIR cluster profiles on disease patterns of Canadian Aboriginals and other indigenous peoples of the Americas, " European Journal of Human Genetics, vol. 19, no. 12, pp. 1276-1280, 2011.